Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos over-the-counter line of skin care cosmetics products. In addition, it is developing Ameluz for the treatment of basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. The company offers its products primarily in the United States and Europe. Biofrontera AG has a collaboration and partnership agreement with Maruho Co., Ltd. The company was founded in 1997 and is headquartered in Leverkusen, Germany.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BFRA
CUSIPN/A
Phone011-49-2148-7600
Debt
Debt-to-Equity Ratio0.75
Current Ratio8.89
Quick Ratio8.08
Price-To-Earnings
Trailing P/E Ratio-15.39
Forward P/E Ratio-34.63
P/E GrowthN/A
Sales & Book Value
Annual Sales$13.58 million
Price / Sales22.56
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)($0.90)
Net Income$-18,200,000.00
Net Margins-92.12%
Return on Equity-123.87%
Return on Assets-52.29%
Miscellaneous
Employees123
Outstanding Shares22,120,000
Market Cap$307.51 million
BIOFRONTERA AG/ADR (NASDAQ:BFRA) Frequently Asked Questions
What is BIOFRONTERA AG/ADR's stock symbol?
BIOFRONTERA AG/ADR trades on the NASDAQ under the ticker symbol "BFRA."
When is BIOFRONTERA AG/ADR's next earnings date?
What price target have analysts set for BFRA?
2 Wall Street analysts have issued 1 year price objectives for BIOFRONTERA AG/ADR's stock. Their forecasts range from $19.00 to $20.00. On average, they anticipate BIOFRONTERA AG/ADR's stock price to reach $19.50 in the next year. This suggests a possible upside of 40.8% from the stock's current price. View Analyst Price Targets for BIOFRONTERA AG/ADR.
What is the consensus analysts' recommendation for BIOFRONTERA AG/ADR?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOFRONTERA AG/ADR in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIOFRONTERA AG/ADR.
Who are some of BIOFRONTERA AG/ADR's key competitors?
Some companies that are related to BIOFRONTERA AG/ADR include Omeros (OMER), Esperion Therapeutics (ESPR), Intra-Cellular Therapies (ITCI), Retrophin (RTRX), Athenex (ATNX), Apellis Pharmaceuticals (APLS), Zai Lab (ZLAB), Lexicon Pharmaceuticals (LXRX), Karyopharm Therapeutics (KPTI), Viking Therapeutics (VKTX), Alder Biopharmaceuticals (ALDR), Rhythm Pharmaceuticals (RYTM), Vanda Pharmaceuticals (VNDA), CannTrust (CNTTF) and Eagle Pharmaceuticals (EGRX).
Who are BIOFRONTERA AG/ADR's key executives?
BIOFRONTERA AG/ADR's management team includes the folowing people:
- Prof. Hermann Lübbert, Co-Founder, Chairman of Management Board & CEO (Age 62)
- Mr. Thomas Schaffer, CFO & Member of Management Board (Age 55)
- Mr. Christoph Dünwald, Chief Commercial Officer, Head of Sales & Marketing and Additional Member of Management Board (Age 50)
- Mr. Alexander Richardson, Head of UK Sales Team
When did BIOFRONTERA AG/ADR IPO?
(BFRA) raised $18 million in an IPO on Wednesday, February 14th 2018. The company issued 1,500,000 shares at a price of $11.00-$13.00 per share. Benchmark served as the underwriter for the IPO and Dawson James Securities and Lake Street Capital Markets were co-managers.
When did BIOFRONTERA AG/ADR's lock-up period expire?
BIOFRONTERA AG/ADR's lock-up period expired on Monday, August 13th. BIOFRONTERA AG/ADR had issued 1,215,000 shares in its initial public offering on February 14th. The total size of the offering was $12,004,200 based on an initial share price of $9.88. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period.
Who are BIOFRONTERA AG/ADR's major shareholders?
BIOFRONTERA AG/ADR's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Opaleye Management Inc. (1.77%).
Which major investors are buying BIOFRONTERA AG/ADR stock?
BFRA stock was acquired by a variety of institutional investors in the last quarter, including Opaleye Management Inc..
How do I buy shares of BIOFRONTERA AG/ADR?
Shares of BFRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BIOFRONTERA AG/ADR's stock price today?
One share of BFRA stock can currently be purchased for approximately $13.85.
How big of a company is BIOFRONTERA AG/ADR?
BIOFRONTERA AG/ADR has a market capitalization of $307.51 million and generates $13.58 million in revenue each year. The company earns $-18,200,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. BIOFRONTERA AG/ADR employs 123 workers across the globe.
What is BIOFRONTERA AG/ADR's official website?
How can I contact BIOFRONTERA AG/ADR?
BIOFRONTERA AG/ADR's mailing address is HEMMELRATHER WEG 201, LEVERKUSEN 2M, D-51377. The company can be reached via phone at 011-49-2148-7600 or via email at [email protected]
MarketBeat Community Rating for BIOFRONTERA AG/ADR (NASDAQ BFRA)
MarketBeat's community ratings are surveys of what our community members think about BIOFRONTERA AG/ADR and other stocks. Vote "Outperform" if you believe BFRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BFRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
